Jennison Associates
FATE icon

Jennison Associates’s Fate Therapeutics FATE Stock Holding History

Jennison Associates’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-383,714
Closed -$22.7M – 682
2021
Q3 		$22.7M Sell
383,714
-360,278
-48% -$28.3M 0.01% 343
2021
Q2 		$64.6M Hold
743,992
– – 0.04% 178
2021
Q1 		$61.3M Sell
743,992
-31,365
-4% -$3.01M 0.04% 187
2020
Q4 		$70.5M Sell
775,357
-240,712
-24% -$14.9M 0.05% 153
2020
Q3 		$40.6M Buy
1,016,069
+3,644
+0.4% +$127K 0.03% 216
2020
Q2 		$34.7M Sell
1,012,425
-106,950
-10% -$3.19M 0.03% 217
2020
Q1 		$24.9M Sell
1,119,375
-187,631
-14% -$4.75M 0.03% 227
2019
Q4 		$25.6M Buy
1,307,006
+7,638
+0.6% +$121K 0.03% 276
2019
Q3 		$20.2M Buy
1,299,368
+751,446
+137% +$14.4M 0.02% 317
2019
Q2 		$11.1M Buy
547,922
+60,878
+12% +$1.1M 0.01% 424
2019
Q1 		$8.56M Buy
487,044
+253,540
+109% +$4M 0.01% 440
2018
Q4 		$3M Sell
233,504
-66,496
-22% -$927K ﹤0.01% 497
2018
Q3 		$4.89M Buy
+300,000
New +$3.55M ﹤0.01% 500

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates's FATE Position: Q4 2021 in Review

Jennison Associates sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 383,714 shares — an estimated $22.7M sold.

Jennison Associates first reported a position in FATE in Q3 2018 and held it in 13 quarters. The position peaked at $70.5M in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Jennison Associates reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jennison Associates sold 383,714 Fate Therapeutics shares in Q4 2021, an estimated $22.7M.
  • Jennison Associates first reported a position in Fate Therapeutics in Q3 2018 and held it in 13 quarters.
  • Jennison Associates's Fate Therapeutics position peaked at $70.5M in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Jennison Associates's 13F filing for Q4 2021, filed 8 Feb 2022.